By reconstructing the tumor microenvironment using ER+BCCs, TAFs, and the immune cells from the same primary tumors, we demonstrate that the effectiveness of endocrine therapy (Tam) can be significantly augmented in the presence of IL1R1 and PDGFRβ blockers. The gene discussed is PDGFRB; the disease is neoplasm.